πŸ‡ΊπŸ‡Έ FDA
Patent

US 11452721

Formulations of pimavanserin

granted A61KA61K31/4468A61K47/38

Quick answer

US patent 11452721 (Formulations of pimavanserin) held by ACADIA Pharmaceuticals Inc. expires Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ACADIA Pharmaceuticals Inc.
Grant date
Tue Sep 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/4468, A61K47/38, A61K9/1652, A61K9/1688